Cancer name Non Small Cell Lung Cancer
Cancer Type NSCLC
Immunotherapy type Immune Checkpoint Therapy
Treatment M7825(Bintrafusp alfa)
Drugstatus Investigational
Drugbank ID DB15388
Checkpoints PD-L2
Signature Type Protein
Signature Smad3
Official Symbol SMAD3
Mode of action PHOS_D_DOWN
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description Analysis of expression of phosphorylated and total Smad2 and Smad3 in A549 cells untreated or treated with TGF-b1 alone or in combination witha-PD-L1 or M7824 demonstrated the ability of M7824 to markedly prevent activation of both Smad2 and Smad3 in response to TGF-b1.
PMID 29123964
Title A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7825) efficiently reverts mesenchymalization of human lung cancer cells